ライフサイエンスコーパス: immune deviation

1 inducing regulatory T and B lymphocytes and immune deviation.

2 of animals with anterior chamber-associated immune deviation.

3 iform tolerance but did not prevent Th2-type immune deviation.

4 fective in mediating tumor regression, i.e., immune deviation.

5 C of these eyes still promoted AC-associated immune deviation.

6 monocytes facilitated graft prolongation via immune deviation.

7 subretinal space or the VC of eyes elicited immune deviation.

8 ion of antigen-specific T cells and not with immune deviation.

9 and CD40, molecules associated with Th1-type immune deviation.

10 fas ligand-mediated apoptosis and Th1 to Th2 immune deviation.

11 e induction of high-dose T cell tolerance or immune deviation.

12 perimental autoimmune encephalomyelitis, via immune deviation.

13 tropenia and immature dendritic cells to the immune deviation.

14 suppressed, but rather displayed evidence of immune deviation.

15 model of tolerance is called a.c.-associated immune deviation.

16 to normal recipients to test for transfer of immune deviation.

17 anaphylactic shock, and thus does not cause immune deviation.

18 ogeneic-specific anterior chamber-associated immune deviation.

19 ation similar to anterior chamber-associated immune deviation.

20 failed to induce anterior chamber-associated immune deviation.

21 bility to induce anterior chamber-associated immune deviation.

22 be-defined immunologic background leading to immune deviations.

23 the induction of anterior chamber-associated immune deviation; 3) Tregs require IL-17A to mediate a c

24 f DBA/2J mice fail to induce antigen induced immune deviation (a form of tolerance) when treated with

25 c mice to induce anterior chamber-associated immune deviation (ACAID) and promote corneal allograft s

26 eyes to support anterior chamber-associated immune deviation (ACAID) induction after anterior chambe

27 to support anterior chamber (AC)-associated immune deviation (ACAID) induction after injection of ov

28 Anterior chamber-associated immune deviation (ACAID) is a form of peripheral toleran

29 Anterior chamber-associated immune deviation (ACAID) is elicited by an antigen-speci

30 e in vivo anterior chamber (a.c.)-associated immune deviation (ACAID) model of peripheral tolerance,

31 animal model of anterior chamber-associated immune deviation (ACAID) occurs in most mouse strains, A

32 elicited by the anterior chamber-associated immune deviation (ACAID) protocol is characterized by im

33 tudy, we use the anterior chamber-associated immune deviation (ACAID) to demonstrate that central reg

34 bility to induce anterior chamber-associated immune deviation (ACAID) to intracamerally injected solu

35 Anterior chamber-associated immune deviation (ACAID) Tregs were induced by injecting

36 Anterior chamber-associated immune deviation (ACAID), a manifestation of ocular immu

37 ens of mice with anterior chamber-associated immune deviation (ACAID), an eye-derived tolerance evoke

38 s systemic tolerance, termed a.c.-associated immune deviation (ACAID), characterized by Ag-specific i

39 enomenon, termed anterior chamber-associated immune deviation (ACAID), culminates in the generation o

40 , referred to as anterior chamber-associated immune deviation (ACAID), is characterized by impairment

41 tolerance called anterior chamber-associated immune deviation (ACAID), the differentiation of the T r

42 tolerance called Anterior Chamber-Associated Immune Deviation (ACAID), the differentiation of the T r

43 y donor-specific anterior chamber-associated immune deviation (ACAID), this deviant response is not d

44 hways, including anterior chamber-associated immune deviation (ACAID), which has been shown to partic

45 antigen-specific anterior chamber-associated immune deviation (ACAID).

46 n (OVA)-specific anterior chamber associated immune deviation (ACAID).

47 henomenon termed anterior chamber-associated immune deviation (ACAID).

48 mechanism called anterior chamber-associated immune deviation (ACAID).

49 ity (DH), termed anterior chamber associated immune deviation (ACAID).

50 nomenon known as anterior chamber-associated immune deviation (ACAID).

51 tory phenomenon, anterior chamber associated immune deviation (ACAID).

52 pheral immune tolerance termed AC-associated immune deviation (ACAID).

53 , referred to as anterior chamber-associated immune deviation (ACAID).

54 henomenon termed anterior chamber-associated immune deviation (ACAID).

55 made of induced anterior chamber-associated immune deviation (ACAID).

56 nterior chamber (anterior chamber-associated immune deviation; ACAID) is associated in part with CD8+

57 ells was a prerequisite for the induction of immune deviation after antigen presentation in the eye.

58 r of purified DC2 may be exploited to induce immune deviation after transplantation of hematopoietic

59 e immune system in a fashion that results in immune deviation, allowing tumor progression and establi

60 Thus, Th2 immune deviation alone does not account for the exacerba

61 e is increasing evidence that the process of immune deviation already begins in utero, but the underl

62 he subretinal space or the VC did not induce immune deviation, although the AC of these eyes still pr

63 fic regulation of T cells that involves both immune deviation and a new form of cytokine- dependent T

64 Tolerization to dnaJP1 leads to immune deviation and a trend toward clinical efficacy.

65 munization and treated with CT, counteracted immune deviation and abrogated protection.

66 tion mechanism that differs from eye-derived immune deviation and arises even when the BBB is comprom

67 cells are likely expanded in response to Th2 immune deviation and may contribute to tumor progression

68 adhesin 1 (BAD1) exploits host receptors for immune deviation and pathogen survival.

69 ch the PPARalpha agonist gemfibrozil induces immune deviation and protects mice from EAE.

70 the mechanisms of chronic fungal infection, immune deviation, and fungi as disease cofactors.

71 to support anterior chamber (AC)-associated immune deviation, and loss of ocular immune privilege.

72 he eye to support induction of AC-associated immune deviation, and the integrity of the blood/ocular

73 and reduces priming, but does not result in immune deviation; and 3) protection is dependent on pers

74 rafts (>100-day survival) showed evidence of immune deviation, because the MLR to ACI stimulator cell

75 a deviant immune response (brain-associated immune deviation (BRAID)) that was deficient in OVA-spec

76 re B7.2, a molecule associated with Th2-type immune deviation, but not by those expressing more B7.1

77 nyl-coupled T cells into normal mice induced immune deviation, but TNFR2(-/-) 2,4,6-trinitrophenyl-co

78 act not only in the lung to prevent systemic immune deviations, but also within the progenitor compar

79 The objective of this work was to induce immune deviation by mucosal peptide-specific immunothera

80 nt of these T(reg) cells in conjunction with immune deviation by Th2 cells optimally induced protecti

81 Anterior chamber-associated immune deviation can be induced by allogeneic corneal ti

82 A Th1 to Th2 immune deviation can explain the discordant biological r

83 Thus, immune deviation can increase concentrations of pathogen

84 ecessary for tolerance induction, Th1 to Th2 immune deviation cannot be sufficient for tolerance indu

85 e unresponsive state was not associated with immune deviation due to selective secretion of Th1- or T

86 In contrast to immune deviation elicited via the eye, an intact spleen

87 ells is particularly relevant in view of the immune deviation existing in immune-privileged sites suc

88 and p35 peptides were not associated with an immune deviation, expressing levels of IFN-gamma charact

89 These findings demonstrate pronounced immune deviation favoring Th2-type responses after pulse

90 Despite the lack of Th immune deviation, Flt3L ligand-pretreated lymph nodes ex

91 le for promoting anterior chamber-associated immune deviation following injection of Ag into the eye.

92 have considered contributing roles of innate immune deviations following otherwise innocuous infectio

93 BM cells into conditioned recipients induced immune deviation for adaptive B-cell immunity, preventin

94 The subretinal space supports immune deviation for histoincompatible tumor cells and s

95 KL as an adjuvant for immunotherapy mediates immune deviation from a pathological Th2-dominated respo

96 antation and has recently been thought to be immune deviation from the inflammatory Th1 response to a

97 We conclude that type 2 immune deviation has differential effects on CD4+ and CD

98 the severity of allograft rejection, as such immune deviation has proven highly effective in the trea

99 votal early events in other systems, such as immune deviation in childhood to a helper T cell type 2

100 e studied the therapeutic benefit vs risk of immune deviation in experimental allergic encephalomyeli

101 n of antigen-specific regulatory T cells; or immune deviation in favor of TH1 responses.

102 is highly effective in producing Th1 to Th2 immune deviation in several model systems (i.e., fully M

103 t increased c-Maf sumoylation contributes to immune deviation in T1D by reducing c-Maf access to and

104 Disease suppression is associated with immune deviation in the periphery and with suppression o

105 with OVA in the presence of TGF-beta2 induce immune deviation in vivo (impaired delayed hypersensitiv

106 with our previous reports, indicate that an immune deviation in which intragraft Th1-type cytokines

107 nnate immune defects as a cause for systemic immune deviations in response to otherwise innocuous inf

108 w (BM) cell apoptosis associated with innate immune deviations in the BM in response to Pneumocystis

109 We suggest that "immune deviation" in NOD-IL-4 mice is mediated by the pa

110 The eye itself contributes to immune deviation, in part by displaying unique immunoreg

111 mechanisms, and instead display a peripheral immune deviation including differentiation into IL-10-se

112 D4+ and CD8+ T cells before and after type 2 immune deviation induced by IL-4 plus anti-IFN-gamma Ab.

113 Immune deviation induced by intraocular injection of sol

114 okine assays, there were similarities to the immune deviation induced by intraocular inoculation in t

115 Th2 immune deviation induced with keyhole limpet hemocyanin

116 Immune deviation-inducing hybridomas up-regulated expres

117 In this study immune deviation into a Th2 (IL-4) response was associat

118 D4+ Th1 cell-mediated autoimmune disease via immune deviation is an attractive potential therapeutic

119 e efferent CD8(+) Tr cell in a.c.-associated immune deviation is dependent on IL-10-producing, CD1d-r

120 Anterior chamber-associated immune deviation may contribute to the maintenance of co

121 is actively maintained and is mediated by an immune deviation mechanism that differs from eye-derived

122 enotype, to test whether either apoptotic or immune deviation mechanisms apply to cytokine-producing

123 In patients with AD, an underlying immune deviation might result in higher susceptibility o

124 0 days of survival) demonstrated evidence of immune deviation; mixed lymphocyte reaction to ACI stimu

125 specific hyporesponsiveness to IRBP without immune deviation, no evidence for apoptosis either by th

126 underlying mechanisms indicated that neither immune deviation nor induction of regulatory cells was a

127 Thus, neonatal "tolerization" induces immune deviation, not tolerance in the immunological sen

128 Type 2 immune deviation of allospecific CD4+ T cells resulted i

129 Differences in immune deviation of CD4(+) T cells cannot be explained b

130 olerogenic functional phenotype, and 2) that immune deviation of responses to an inflammatory epitope

131 he hypothesis that oral tolerance induces an immune deviation of T cells, peripheral blood mononuclea

132 Immune deviation of T-cell responses to the beta-cell au

133 Protection is mediated by immune deviation of the anti-myelin basic protein (MBP)

134 , CRAg-sensitized mice is coincident with an immune deviation of the lung inflammatory response, inde

135 capacity of the corneal allograft to induce immune deviation of the systemic immune response.

136 onjunctivitis to evaluate the effects of Th2 immune deviation on corneal allograft survival and possi

137 mice were used to determine the presence of immune deviation or other evidence of immunoregulation,

138 rticularly in anatomical sites which exhibit immune deviation or privilege.

139 Thus, Th1 to Th2 immune deviation produces prolonged engraftment as compa

140 Hence, Th1-to-Th2 immune deviation provides only a partial explanation for

141 utic strategies that aim at the induction of immune deviation show little efficacy in the established

142 phage hybridoma no. 63, both of which induce immune deviation similar to anterior chamber-associated

143 ransforming growth factor (TGF)-beta2 induce immune deviation similar to that evoked by injection of

144 by immature dendritic cells can result in an immune deviation similar to that produced by transient T

145 gest that the ultimate success of Th2-to-Th1 immune deviation strategies will rely on the efficient a

146 Ocular immune deviation studies have relied on intraocular inje

147 nisms, including induction of T-cell anergy, immune deviation, T regulatory cell activity, and promot

148 on of regulatory T cell activity, Th2 to Th1 immune deviation, Th1 crossregulation of Th2 immune resp

149 ization is mediated more through Ag-specific immune deviation than via suppression of allergic sensit

150 skin condition, as well as on the underlying immune deviation that might play a role in comorbidities

151 nse to antigens in the diet and the basis of immune deviation that results in immunoglobulin E (IgE)

152 IL-10 are responsible for the activation of immune deviation through interaction with antigen-presen

153 This was achieved through immune deviation to a T-helper-cell response with increa

154 E protected them from developing EAE through immune deviation to a Th2 response.

155 n a variety of autoimmune disorders in which immune deviation to a Th2 type of response is desirable.

156 f the subretinal space and the VC to support immune deviation to antigens injected locally.

157 basis for the frequent failure of Th1 to Th2 immune deviation to blunt the severity of allograft reje

158 leviation of allergy is not achieved through immune deviation to Th1, but is linked to expansion of r

159 From 8 wk onwards an immune deviation to the p38-specific response was observ

160 aft cytokine gene expression to test whether immune deviation to the T helper (Th) 2 response is asso

161 loligands in the graft may all contribute to immune deviation to the Th2 response.

162 h2 cell functions, it has been proposed that immune deviation toward Th1 can protect against asthma a

163 hether cyclophosphamide-treated patients had immune deviation toward Th2 responses.

164 Immune deviation toward type 2 (Th2, Tc2) response has b

165 ntial use of therapeutic approaches based on immune deviation toward type 2 responses.

166 nctions in several ways, it is believed that immune deviation towards Th2 can prevent or cure autoimm

167 on systems there would seem to be a phase of immune deviation towards Th2 cytokines, like IL-4 and IL

168 ulmonary immune activation, causing systemic immune deviations triggering BMF in this model.

169 Importantly, GAD65-specific immune deviation was dependent on pDNA-encoded IL-4.

170 Immune deviation was not dependent on NK or B cells.

171 However, immune deviation was unsuccessful in the latter animals,

172 y of pDNA vaccination to mediate Ag-specific immune deviation, we examined the immunotherapeutic effi

173 re essential for anterior chamber-associated immune deviation, we postulated that the survival of C57

174 c cells, modulation of B-cell responses, and immune deviation were proposed to be responsible for the

175 at are pulsed with Ag into cells that induce immune deviation when injected into naive mice.

176 s, and to induce anterior chamber associated immune deviation when injected into the eye of naive all

177 grafts to induce anterior chamber associated immune deviation when placed in the anterior chamber, no

178 donor T cells induce less GVHD due to a Th2 immune deviation while GVL activity is slightly diminish